Inventiva Aktie

2,37 EUR -0,13 EUR -5,01 %

16:07:02

STU

2,58 EUR -0,02 EUR -0,77 %

20.11.2024

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.225,95 Mio. EUR

Div. Rendite0,00%

WKNA2DLV9

ISINFR0013233012

SymbolIVEVF

Inventiva Aktien News

Sortieren:Datum Meistgelesen

20.11.24GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of November 4, 2024

20.11.24GlobeNewswireCombined General Meeting of December 11, 2024 - Availability of the preparatory documents

15.11.24GlobeNewswireInventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® lat

WerbungInventiva-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.10.24GlobeNewswireInventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

21.10.24GlobeNewswireInventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

14.10.24GlobeNewswireInventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

14.10.24BenzingaWhy Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

14.10.24GlobeNewswireInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

14.10.24GlobeNewswireInventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

01.10.24ZacksInventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

25.09.24GlobeNewswireInventiva provides a corporate update and reports its unaudited 2024 first-half financial results

31.07.24GlobeNewswireInventiva Reports Preliminary 2024 First-Half Financial Information¹

25.07.24GlobeNewswireInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

19.07.24GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

18.07.24GlobeNewswireInventiva announces a €20.1 million issuance of royalty certificates

05.07.24GlobeNewswireInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

21.06.24GlobeNewswireDescription of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

21.06.24GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

18.06.24ZacksDown -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)

30.05.24GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30.05.24GlobeNewswireCombined General Meeting of June 20, 2024 - Availability of the preparatory documents

22.05.24GlobeNewswireInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

21.05.24GlobeNewswireInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

16.05.24GlobeNewswireInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

13.05.24GlobeNewswireInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with

03.04.24GlobeNewswireInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

28.03.24GlobeNewswireInventiva announces the nomination of Andre Turenne as Director

27.03.24GlobeNewswireInventiva reports its 2023 full-year results

22.03.24GlobeNewswireInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

18.03.24GlobeNewswireInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

13.03.24GlobeNewswireInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

07.03.24GlobeNewswireInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

16.02.24BenzingaWhy Is Liver Disease-Focused Inventiva Stock Trading Lower Today?

15.02.24GlobeNewswireInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

24.01.24GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

10.01.24GlobeNewswireInventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

20.12.23GlobeNewswireInventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

04.12.23GlobeNewswireInventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

21.11.23GlobeNewswireInventiva reports 2023 Third Quarter Financial Information¹

06.11.23GlobeNewswireInventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023

Inventiva News

Inventiva News: auf dieser Seite finden Sie alle Inventiva News und Nachrichten zur Inventiva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Inventiva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Inventiva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.